This post would never end if I shared every photo from 2025. And, honestly, that wouldn’t tell the real story anyway. So, I gave myself a boundary: two photos per month. Not too little, not too much. Just enough to capture the moments that made me pause, laugh, adapt or feel especially grateful. This is…
Month: January 2026
Switching sideways or upwords..The only way is Up..Baby
Tweet This is what they say Is horizontal switching a valid strategy in the treatment of MS? “For people living with multiple sclerosis (MS), treatment changes are often necessary due to inadequate response, safety concerns, or personal preferences. These treatment switches can follow different strategies. One option is a “vertical switch,” where patients move to…
Myelin-targeting drug Lucid-MS inches closer to testing in patients
Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic studies were designed to evaluate any potential harmful…
Elizabeth Rash – MSAA’s January 2026 Artist of the Month
MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Elizabeth Rash as January’s … Continue reading → Source: blog.mymsaa.org
Cladribine Real Life
Tweet Lucchini M, Borriello G, Haggiag S, Nicoletti CG, Fantozzi R, Buscarinu MC, Ferrazzano G, Cortese A, Marinelli F, Monteleone F, Centonze D, Conte A, Ferraro E, Gasperini C, Marfia GA, Pozzilli C, Salvetti M, Barbuti E, Bellucci G, Bianco A, Carlomagno V, Cruciani A, De Giglio L, Dionisi C, Ianniello A, Malimpensa L, Nasello…
FDA says Tolebrutinib is a Shania
Tweet Tolebrutinib inhibited clinical non-relapsing secondary progressive MS and thus became the first drug to do this. However whilst it showed a clinical slowing of disability, it failed to have benefit in other measures. More recently a trial was done in primary progressive MS and tolebrutininb failed to affect progression. The Federal Drug Administration has…